Table 1.
Baseline characteristics of the study participant according to ESAs randomization group during P1
|
C.E.R.A |
Darbepoetin alfa |
p-value | |
|---|---|---|---|
| (n = 15) | (n = 15) | ||
|
Sex (male), N (%) |
8 (53.3%) |
9 (60%) |
0.71 |
|
Age, year (mean, SD) |
70.5 (9.7) |
69.3 (10.3) |
0.73 |
|
Dry weight, kg (mean, SD) |
66.8 (18.5) |
77.0 (16.1) |
0.12 |
|
Diabetic, % |
53 |
47 |
0.71 |
|
Hypertensive, % |
93 |
93 |
1.0 |
|
Dialysis duration, hours/week (mean, SD) |
11.5 (1) |
11.1 (1) |
0.34 |
|
Time on dialysis, years (mean, SD) |
3.1 (2.9) |
2.5 (1.9) |
0.46 |
|
Hemoglobin, g/dl (mean, SD) |
10.9 (1.3) |
11.3 (1.1) |
0.37 |
|
Reticulocyte count, cells/μl (mean, SD) |
34147 (12823) |
38711 (20368) |
0.47 |
|
Ferritin, μg/l (mean, SD) |
357.4 (213.5) |
361.8 (127.3) |
0.95 |
|
Iron dose, mg/month (mean, SD) |
173.3 (103.3) |
186.7 (51.6) |
0.66 |
| ESA dose, μg/month (median, IQR) | 120 (75–158) | 100 (64–146) | 0.32 |
SD Standard deviation, IQR Inter-quartile range.